Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Georges Hatoum

Georges Hatoum

JFK Comprehensive Cancer Institute, USA

Title: The radiation treatment of ocular melanoma: Techniques and advances

Biography

Biography: Georges Hatoum

Abstract

Statement of the Problem: Ocular melanoma is a rare subset of melanoma, yet comprises the majority of ocular malignancies. Management of ocular melanoma consists of either enucleation or glob-preserving therapies including radiation therapy (RT) and surgical resection. There are generally two categories RT for ocular melanoma, radioactive plaque brachytherapy and external beam radiotherapy (EBRT), including charged particle radiation and photon stereotactic radiosurgery (SRS). In this presentation we give an overview of the technical details and clinical efficacies of different RT techniques for ocular melanoma. In an effort to reduce the invasiveness without compromising accuracy, we developed a novel approach of real-time tracking to ocular tumors that can be applied to high-precision RT either with charged particle or photon beams.

 

Methodology & Theoretical Orientation: A novel “pupil tracking” approach uses a derived 2D/3D transformation to relate the pupil’s 2D coordinate captured by a video camera in the image plane with the tumor’s 3D location in the CT space. A motion phantom was development to test the feasibility of this technology with a robotic radiosurgery system.

 

Findings: The results show that the unique 2D/3D transformation algorithm is not only theoretically possible but also consistently reproducible with sub-millimeter accuracy.

Conclusion & Significance: Charged particle RT or SRS can eliminate invasiveness of brachytherapy. Pupil-based tracking can further assure the physical accuracy and achieve optimal clinical outcomes.